BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Transcription profiling by array of human peripheral blood samples from Kawasaki disease patients after treatment with intravenous...

Dataset: Transcription profiling by array of human peripheral blood samples from Kawasaki disease patients after treatment with intravenous immunoglobulin and methylprednisolone

Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone....

Registered by ArrayExpress Uploader
View Dataset

Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone. Intravenous immunoglobulin (IVIG) treatment-resistant patients are high risk of developing coronary artery lesions (CALs) with Kawasaki disease (KD). The IVIG-responsive (Group A; n = 6) and -resistant patients (Group B) were predicted before starting the initial treatment using the Egami scoring system, and randomly allocated a single-IVIG treatment group (Group B1; n = 6) or a IVIG-plus-methylprednisolone (IVMP) combined therapy group (Group B2; n = 5). We investigated transcript abundance in the leukocytes of those patients using microarray analysis. Results: five patients in Group A and 1 patient in Group B1 responded to initial IVIG treatment. All Group B2 patients responded to IVIP-plus-IVMP combined therapy. Prior to performing these treatments, those transcripts related to IVIG-resistance and to the development of CALs, such as IL1R, IL18R, oncostatin M, suppressor of cytokine signaling-3, S100A12 protein, carcinoembryonic antigen-related cell adhesion molecule-1, matrix metallopeptidase-9 and polycythemia rubra vera-1 were more abundant in Group B patients in comparison to Group A patients. Moreover, those transcripts in Group B2 patients were more profoundly and broadly suppressed than Group B1 patients after treatment. Conclusion: this study elucidated the molecular mechanism of the effectiveness of IVIG-plus-IVMP combined therapy. 34 samples of pre- and post-treatment in three groups consisting of predicted as IVIG-responsive patients, given single-IVIG treatment patients and IVIG-plus-IVMP combined therapy group in predicted as IVIG-resistant patients. Samples were analyzed without replicates.

Species:
human

Samples:
34

Source:
E-GEOD-16797

PubMed:
19680167

Updated:
Dec.12, 2014

Registered:
Sep.12, 2014


Factors: (via ArrayExpress)
Sample phenotype clinical treatment
GSM421899 intravenous immunoglobulin responsive none
GSM421900 intravenous immunoglobulin responsive intravenous immunoglobulin
GSM421899 intravenous immunoglobulin responsive none
GSM421900 intravenous immunoglobulin responsive intravenous immunoglobulin
GSM421899 intravenous immunoglobulin responsive none
GSM421900 intravenous immunoglobulin responsive intravenous immunoglobulin
GSM421899 intravenous immunoglobulin responsive none
GSM421900 intravenous immunoglobulin responsive intravenous immunoglobulin
GSM421899 intravenous immunoglobulin responsive none
GSM421900 intravenous immunoglobulin responsive intravenous immunoglobulin
GSM421899 intravenous immunoglobulin responsive none
GSM421900 intravenous immunoglobulin responsive intravenous immunoglobulin
GSM4219 intravenous immunoglobulin resistant none
GSM421912 intravenous immunoglobulin resistant intravenous immunoglobulin
GSM4219 intravenous immunoglobulin resistant none
GSM421912 intravenous immunoglobulin resistant intravenous immunoglobulin
GSM4219 intravenous immunoglobulin resistant none
GSM421912 intravenous immunoglobulin resistant intravenous immunoglobulin
GSM4219 intravenous immunoglobulin resistant none
GSM421912 intravenous immunoglobulin resistant intravenous immunoglobulin
GSM4219 intravenous immunoglobulin resistant none
GSM421912 intravenous immunoglobulin resistant intravenous immunoglobulin
GSM4219 intravenous immunoglobulin resistant none
GSM421912 intravenous immunoglobulin resistant intravenous immunoglobulin
GSM4219 intravenous immunoglobulin resistant none
GSM421924 intravenous immunoglobulin resistant intravenous immunoglobulin and methylprednisolone
GSM4219 intravenous immunoglobulin resistant none
GSM421924 intravenous immunoglobulin resistant intravenous immunoglobulin and methylprednisolone
GSM4219 intravenous immunoglobulin resistant none
GSM421924 intravenous immunoglobulin resistant intravenous immunoglobulin and methylprednisolone
GSM4219 intravenous immunoglobulin resistant none
GSM421924 intravenous immunoglobulin resistant intravenous immunoglobulin and methylprednisolone
GSM4219 intravenous immunoglobulin resistant none
GSM421924 intravenous immunoglobulin resistant intravenous immunoglobulin and methylprednisolone

Tags

  • artery
  • cell
  • cell adhesion molecule
  • coronary artery
  • cytokine
  • disease
  • group b
  • immunoglobulin
  • kawasaki disease
  • polycythemia
  • protein

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2023 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use